Population pharmacokinetics of hydroxyurea for children and adolescents with sickle cell disease.
about
Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia.Pharmacokinetics and bioequivalence of a liquid formulation of hydroxyurea in children with sickle cell anemiaPopulation Pharmacokinetic and Exposure-Response Analyses of Prasugrel in Pediatric Patients with Sickle Cell Anemia.A Clinically Meaningful Fetal Hemoglobin Threshold for Children with Sickle Cell Anemia During Hydroxyurea Therapy.Hydroxycarbamide in children with sickle cell anaemia after first-dose vs. chronic therapy: pharmacokinetics and predictive models for drug exposure.
P2860
Population pharmacokinetics of hydroxyurea for children and adolescents with sickle cell disease.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Population pharmacokinetics of ...... ents with sickle cell disease.
@en
Population pharmacokinetics of ...... ents with sickle cell disease.
@nl
type
label
Population pharmacokinetics of ...... ents with sickle cell disease.
@en
Population pharmacokinetics of ...... ents with sickle cell disease.
@nl
prefLabel
Population pharmacokinetics of ...... ents with sickle cell disease.
@en
Population pharmacokinetics of ...... ents with sickle cell disease.
@nl
P2093
P2860
P356
P1476
Population pharmacokinetics of ...... ents with sickle cell disease.
@en
P2093
Gregory L Kearns
Julie A Panepinto
Kathleen A Neville
Robert I Liem
Susan M Abdel-Rahman
Uttam Garg
P2860
P304
P356
10.1002/JCPH.303
P577
2014-04-11T00:00:00Z